Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Bladder Carcinoma: early-phase trial registry
3 of 3 indexed Metastatic Bladder Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Metastatic Bladder Carcinoma: 3 US clinical trials tracked, 3 recruiting.
Metastatic Bladder Carcinoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Roswell Park Cancer Institute, running 1 of these trials.
Enrollment posture brief
Registry condition metastatic-bladder-carcinoma
OPEN 3 | RECR 100% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Metastatic Bladder Carcinoma lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Bladder Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Bladder Carcinoma is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers
Roswell Park Cancer Institute
NCT06414317
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
National Cancer Institute (NCI)
NCT03375307
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Emory University
NCT05756569
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Bladder Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Bladder Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Bladder Carcinoma page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Metastatic Bladder Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Roswell Park Cancer Institute sponsors the most Metastatic Bladder Carcinoma trials on record, review their full trial history before evaluating a specific study. See Roswell Park Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Bladder Carcinoma condition card totals 3 registered trials; most-linked intervention Computed Tomography; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.